{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T09:12:33Z","timestamp":1793351553570,"version":"4.5.0"},"reference-count":91,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:00:00Z","timestamp":1707264000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019717","name":"AstraZeneca Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019717","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archivos de Bronconeumolog\u00eda"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.arbres.2024.01.013","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T16:39:46Z","timestamp":1706805586000},"page":"226-237","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Multidisciplinary Management of Patients With Chronic Obstructive Pulmonary Disease and Cardiovascular Disease"],"prefix":"10.1016","volume":"60","author":[{"given":"Javier","family":"de Miguel-D\u00edez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"N\u00fa\u00f1ez Villota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salud","family":"Santos P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00e1s","family":"Manito Lorite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardino","family":"Alc\u00e1zar Navarrete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Francisco","family":"Delgado Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jos\u00e9","family":"Soler-Catalu\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domingo","family":"Pascual Figal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Sobradillo Ecenarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jos\u00e9","family":"G\u00f3mez Doblas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arbres.2024.01.013_bib0460","doi-asserted-by":"crossref","DOI":"10.1177\/1753465817750524","article-title":"Defining the relationship between COPD and CVD: what are the implications for clinical practice?","volume":"12","author":"Morgan","year":"2018","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.arbres.2024.01.013_bib0465","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/eurjhf\/hfn013","article-title":"Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology","volume":"11","author":"Hawkins","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.arbres.2024.01.013_bib0470","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.arbres.2024.01.013_bib0475","doi-asserted-by":"crossref","unstructured":"Rogliani P, Calzetta L. Cardiovascular disease in COPD. In: Mart\u00ednez-Garc\u00eda M\u00c1, P\u00e9pin JL, Cazzola M, eds. Cardiovascular complications of respiratory disorders. European Respiratory Society; 2020:47\u201365. doi:10.1183\/2312508X. 10027319.","DOI":"10.1183\/2312508X.10027319"},{"key":"10.1016\/j.arbres.2024.01.013_bib0480","doi-asserted-by":"crossref","DOI":"10.1136\/thoraxjnl-2021-218333","article-title":"Cardiovascular disease in chronic obstructive pulmonary disease: a narrative review","author":"Balbirsingh","year":"2022","journal-title":"Thorax"},{"key":"10.1016\/j.arbres.2024.01.013_bib0485","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0002-9149(00)01393-X","article-title":"Importance of heart failure with preserved systolic function in patients > or =65 years of age. CHS Research Group. Cardiovascular Health Study","volume":"87","author":"Kitzman","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.arbres.2024.01.013_bib0490","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1164\/rccm.201201-0034OC","article-title":"Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease","volume":"186","author":"Divo","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.arbres.2024.01.013_bib0495","doi-asserted-by":"crossref","first-page":"871","DOI":"10.2147\/COPD.S49621","article-title":"Epidemiology and clinical impact of major comorbidities in patients with COPD","volume":"9","author":"Smith","year":"2014","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.arbres.2024.01.013_bib0500","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.2147\/COPD.S393535","article-title":"COPD exacerbation syndrome: the Spanish perspective on an old dilemma","volume":"17","author":"Soler-Cataluna","year":"2022","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.arbres.2024.01.013_bib0505","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.arbres.2021.05.033","article-title":"Spanish COPD guidelines (GesEPOC) 2021 update diagnosis and treatment of COPD exacerbation syndrome","volume":"58","author":"Soler-Cataluna","year":"2022","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2024.01.013_bib0510","doi-asserted-by":"crossref","first-page":"e024350","DOI":"10.1161\/JAHA.121.024350","article-title":"Time-dependent risk of cardiovascular events following an exacerbation in patients with chronic obstructive pulmonary disease: post hoc analysis from the IMPACT trial","volume":"11","author":"Dransfield","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.arbres.2024.01.013_bib0515","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1164\/rccm.201711-2239OC","article-title":"Exacerbations of chronic obstructive pulmonary disease and cardiac events. A post hoc cohort analysis from the SUMMIT randomized clinical trial","volume":"198","author":"Kunisaki","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.arbres.2024.01.013_bib0520","first-page":"217","article-title":"Comorbidities in current COPD guidelines","volume":"59","author":"Bakke","year":"2013","journal-title":"Eur Respir Monogr"},{"key":"10.1016\/j.arbres.2024.01.013_bib0525","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1378\/chest.09-1264","article-title":"High prevalence of undiagnosed airflow limitation in patients with cardiovascular disease","volume":"137","author":"Soriano","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.arbres.2024.01.013_bib0530","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S2213-2600(15)00509-3","article-title":"Cardiac dysfunction during exacerbations of chronic obstructive pulmonary disease","volume":"4","author":"MacDonald","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arbres.2024.01.013_bib0535","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S2213-2600(15)00241-6","article-title":"Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis","volume":"3","author":"Chen","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arbres.2024.01.013_bib0540","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1378\/chest.128.4.2068","article-title":"COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program","volume":"128","author":"Sidney","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.arbres.2024.01.013_bib0545","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2147\/COPD.S174443","article-title":"A prospective study of the clinical outcomes and prognosis associated with comorbid COPD in the atrial fibrillation population","volume":"14","author":"Rodriguez-Manero","year":"2019","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.arbres.2024.01.013_bib0550","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.annepidem.2005.04.008","article-title":"Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients","volume":"16","author":"Curkendall","year":"2006","journal-title":"Ann Epidemiol"},{"key":"10.1016\/j.arbres.2024.01.013_bib0555","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1001\/jama.1994.03520190043033","article-title":"Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study","volume":"272","author":"Anthonisen","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.arbres.2024.01.013_bib0560","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1183\/09031936.00012408","article-title":"Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD","volume":"32","author":"Mannino","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2024.01.013_bib0565","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00408-011-9301-8","article-title":"Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4-year UPLIFT(R) trial","volume":"189","author":"Halpin","year":"2011","journal-title":"Lung"},{"key":"10.1016\/j.arbres.2024.01.013_bib0570","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1136\/thx.2005.040527","article-title":"Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease","volume":"60","author":"Soler-Cataluna","year":"2005","journal-title":"Thorax"},{"key":"10.1016\/j.arbres.2024.01.013_bib0575","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1136\/thx.2009.128082","article-title":"Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care","volume":"65","author":"Feary","year":"2010","journal-title":"Thorax"},{"key":"10.1016\/j.arbres.2024.01.013_bib0580","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1164\/rccm.201512-2480OC","article-title":"Lung function abnormalities in smokers with ischemic heart disease","volume":"194","author":"Franssen","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.arbres.2024.01.013_bib0585","doi-asserted-by":"crossref","first-page":"e019238","DOI":"10.1161\/JAHA.120.019238","article-title":"Clinical characteristics and outcomes of patients with heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: insights from PARADIGM-HF","volume":"10","author":"Ehteshami-Afshar","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.arbres.2024.01.013_bib0590","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.2147\/COPD.S203215","article-title":"The etiologic origins for chronic obstructive pulmonary disease","volume":"14","author":"Huang","year":"2019","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.arbres.2024.01.013_bib0595","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.rmed.2015.05.021","article-title":"Chronic obstructive pulmonary disease and coronary disease: COPDCoRi, a simple and effective algorithm for predicting the risk of coronary artery disease in COPD patients","volume":"109","author":"Cazzola","year":"2015","journal-title":"Respir Med"},{"key":"10.1016\/j.arbres.2024.01.013_bib0600","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s10557-014-6569-y","article-title":"Chronic obstructive pulmonary disease and ischemic heart disease comorbidity: overview of mechanisms and clinical management","volume":"29","author":"Campo","year":"2015","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.arbres.2024.01.013_bib0605","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S2213-2600(17)30434-4","article-title":"Lung function in early adulthood and health in later life: a transgenerational cohort analysis","volume":"5","author":"Agusti","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arbres.2024.01.013_bib0610","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jaci.2016.05.011","article-title":"Inflammatory mechanisms in patients with chronic obstructive pulmonary disease","volume":"138","author":"Barnes","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.arbres.2024.01.013_bib0615","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0057-2018","article-title":"Cardiovascular disease and COPD: dangerous liaisons?","volume":"27","author":"Rabe","year":"2018","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.arbres.2024.01.013_bib0620","doi-asserted-by":"crossref","first-page":"649512","DOI":"10.3389\/fcvm.2021.649512","article-title":"Chronic obstructive pulmonary disease and the cardiovascular system: vascular repair and regeneration as a therapeutic target","volume":"8","author":"Karnati","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.arbres.2024.01.013_bib0625","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1111\/all.15426","article-title":"The impact of type 2 immunity and allergic diseases in atherosclerosis","volume":"77","author":"Fern\u00e1ndez-Gallego","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.arbres.2024.01.013_bib0630","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.jacbts.2019.07.002","article-title":"Associations of interleukin-5 with plaque development and cardiovascular events","volume":"4","author":"Knutsson","year":"2019","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.arbres.2024.01.013_bib0635","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1378\/chest.13-1809","article-title":"Arterial stiffness in COPD","volume":"145","author":"Vivodtzev","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.arbres.2024.01.013_bib0640","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1378\/chest.09-2810","article-title":"Decreasing cardiac chamber sizes and associated heart dysfunction in COPD: role of hyperinflation","volume":"138","author":"Watz","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.arbres.2024.01.013_bib0645","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa0808836","article-title":"Percent emphysema, airflow obstruction, and impaired left ventricular filling","volume":"362","author":"Barr","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2024.01.013_bib0650","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1161\/CIRCULATIONAHA.113.001653","article-title":"Pulmonary hyperinflation and left ventricular mass: the multi-ethnic study of atherosclerosis COPD study","volume":"127","author":"Smith","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.arbres.2024.01.013_bib0655","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.arbres.2024.01.013_bib0660","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.jacc.2018.06.051","article-title":"Cardiac troponin I and cardiovascular risk in patients with chronic obstructive pulmonary disease","volume":"72","author":"Adamson","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arbres.2024.01.013_bib0665","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12931-020-01430-z","article-title":"Cardiac biomarkers of prognostic importance in chronic obstructive pulmonary disease","volume":"21","author":"Nilsson","year":"2020","journal-title":"Respir Res"},{"key":"10.1016\/j.arbres.2024.01.013_bib0670","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s00059-019-4814-7","article-title":"COPD and heart failure: differential diagnosis and comorbidity","volume":"44","author":"G\u00fcder","year":"2019","journal-title":"Herz"},{"key":"10.1016\/j.arbres.2024.01.013_bib0675","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12890-016-0345-7","article-title":"B-type natriuretic peptides in chronic obstructive pulmonary disease: a systematic review","volume":"17","author":"Hawkins","year":"2017","journal-title":"BMC Pulm Med"},{"issue":"6\u20137","key":"10.1016\/j.arbres.2024.01.013_bib0680","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.ejheart.2007.01.010","article-title":"Comparison of B-type natriuretic peptide assays for identifying heart failure in stable elderly patients with a clinical diagnosis of chronic obstructive pulmonary disease","volume":"9","author":"Rutten","year":"2007","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.arbres.2024.01.013_bib0685","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/1479972316674393","article-title":"Amino terminal pro brain natriuretic peptide predicts all-cause mortality in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis","volume":"14","author":"Pavasini","year":"2017","journal-title":"Chron Respir Dis"},{"key":"10.1016\/j.arbres.2024.01.013_bib0690","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1002\/ejhf.946","article-title":"What can we learn from pulmonary function testing in heart failure?","volume":"19","author":"Magnussen","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.arbres.2024.01.013_bib0695","unstructured":"Atenci\u00f3n Primaria y Servicio de Cardiolog\u00eda Hospital General Universitario Gregorio Mara\u00f1on. Atenci\u00f3n Integral de las Cardiopat\u00edas. Protocolizaci\u00f3n compartida de los procesos card\u00edacos en un entorno de alta resoluci\u00f3n; 2011."},{"key":"10.1016\/j.arbres.2024.01.013_bib0700","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.arbres.2021.03.005","article-title":"Spanish COPD guidelines (GesEPOC) 2021: updated pharmacological treatment of stable COPD","volume":"58","author":"Miravitlles","year":"2022","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2024.01.013_bib0705","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.arbres.2023.02.009","article-title":"Global initiative for chronic obstructive lung disease 2023 report: GOLD executive summary","volume":"59","author":"Agust\u00ed","year":"2023","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2024.01.013_bib0710","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1164\/rccm.201604-0690SO","article-title":"Chronic obstructive pulmonary disease and cardiac diseases. An urgent need for integrated care","volume":"194","author":"Roversi","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.arbres.2024.01.013_bib0715","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2147\/COPD.S198288","article-title":"Relationship of inhaled long-acting bronchodilators with cardiovascular outcomes among patients with stable COPD: a meta-analysis and systematic review of 43 randomized trials","volume":"14","author":"Li","year":"2019","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.arbres.2024.01.013_bib0720","doi-asserted-by":"crossref","first-page":"907","DOI":"10.2147\/COPD.S130482","article-title":"LABA\/LAMA combinations versus LAMA monotherapy or LABA\/ICS in COPD: a systematic review and meta-analysis","volume":"12","author":"Rodrigo","year":"2017","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.arbres.2024.01.013_bib0725","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.arbres.2021.08.002","article-title":"Spanish COPD guideline (GesEPOC) update: comorbidities. Self-management and palliative care","volume":"58","author":"Lopez-Campos","year":"2022","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2024.01.013_bib0730","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/FJC.0000000000000705","article-title":"Correlation of inhaled long-acting bronchodilators with adverse cardiovascular outcomes in patients with stable COPD: a Bayesian network meta-analysis of randomized controlled trials","volume":"74","author":"Wu","year":"2019","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.arbres.2024.01.013_bib0735","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S2213-2600(18)30054-7","article-title":"Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial","volume":"6","author":"Hohlfeld","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arbres.2024.01.013_bib0740","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","article-title":"Once-daily single-inhaler triple versus dual therapy in patients with COPD","volume":"378","author":"Lipson","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2024.01.013_bib0745","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1916046","article-title":"Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD","volume":"383","author":"Rabe","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2024.01.013_bib0750","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jamainternmed.2013.1016","article-title":"Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease","volume":"173","author":"Gershon","year":"2013","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.arbres.2024.01.013_bib0755","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1001\/jamainternmed.2017.7720","article-title":"Association of cardiovascular risk with inhaled long-acting bronchodilators in patients with chronic obstructive pulmonary disease: a nested case\u2013control study","volume":"178","author":"Wang","year":"2018","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.arbres.2024.01.013_bib0760","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1159\/000369296","article-title":"Bronchogenic stress cardiomyopathy: a case series","volume":"130","author":"Rajwani","year":"2015","journal-title":"Cardiology"},{"key":"10.1016\/j.arbres.2024.01.013_bib0765","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1164\/rccm.202006-2618OC","article-title":"Reduced all-cause mortality in the ETHOS trial of budesonide\/glycopyrrolate\/formoterol for chronic obstructive pulmonary disease. A randomized, double-blind, multicenter, parallel-group study","volume":"203","author":"Martinez","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.arbres.2024.01.013_bib0770","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1164\/rccm.201911-2207OC","article-title":"Reduction in all-cause mortality with fluticasone furoate\/umeclidinium\/vilanterol in patients with chronic obstructive pulmonary disease","volume":"201","author":"Lipson","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.arbres.2024.01.013_bib0775","doi-asserted-by":"crossref","first-page":"d2549","DOI":"10.1136\/bmj.d2549","article-title":"Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study","volume":"342","author":"Short","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.arbres.2024.01.013_bib0780","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0954-6111(03)00168-9","article-title":"Cardioselective beta-blockers for chronic obstructive pulmonary disease: a meta-analysis","volume":"97","author":"Salpeter","year":"2003","journal-title":"Respir Med"},{"key":"10.1016\/j.arbres.2024.01.013_bib0785","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/j.jacc.2010.01.024","article-title":"Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial","volume":"55","author":"Jabbour","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl. 1","key":"10.1016\/j.arbres.2024.01.013_bib0790","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/S0954-6111(11)70010-5","article-title":"Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial","volume":"105","author":"Lainscak","year":"2011","journal-title":"Respir Med"},{"key":"10.1016\/j.arbres.2024.01.013_bib0795","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/eurjhf\/hfp066","article-title":"Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial","volume":"11","author":"Hawkins","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.arbres.2024.01.013_bib0800","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.amjcard.2012.03.019","article-title":"Effect of bisoprolol on respiratory function and exercise capacity in chronic obstructive pulmonary disease","volume":"110","author":"Mainguy","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.arbres.2024.01.013_bib0805","first-page":"CD003566","article-title":"Cardioselective beta-blockers for chronic obstructive pulmonary disease","volume":"2005","author":"Salpeter","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.arbres.2024.01.013_bib0810","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2165\/11532320-000000000-00000","article-title":"Amiodarone: review of pulmonary effects and toxicity","volume":"33","author":"Papiris","year":"2010","journal-title":"Drug Saf"},{"key":"10.1016\/j.arbres.2024.01.013_bib0815","doi-asserted-by":"crossref","DOI":"10.3390\/jcm7100356","article-title":"Drug-induced interstitial lung disease: a systematic review","volume":"7","author":"Skeoch","year":"2018","journal-title":"J Clin Med"},{"key":"10.1016\/j.arbres.2024.01.013_bib0820","article-title":"Pulmonary fibrosis related to amiodarone \u2013 is it a standard pathophysiological pattern? A case-based literature review","volume":"12","author":"Budin","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.arbres.2024.01.013_bib0825","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12931-021-01661-8","article-title":"Beta-blocker therapy in patients with COPD: a systematic literature review and meta-analysis with multiple treatment comparison","volume":"22","author":"Gulea","year":"2021","journal-title":"Respir Res"},{"key":"10.1016\/j.arbres.2024.01.013_bib0830","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1471-2466-12-48","article-title":"Beta-blocker use and COPD mortality: a systematic review and meta-analysis","volume":"12","author":"Etminan","year":"2012","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.arbres.2024.01.013_bib0835","doi-asserted-by":"crossref","first-page":"e113048","DOI":"10.1371\/journal.pone.0113048","article-title":"Beta-blockers reduced the risk of mortality and exacerbation in patients with COPD: a meta-analysis of observational studies","volume":"9","author":"Du","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.arbres.2024.01.013_bib0840","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1136\/thoraxjnl-2015-207251","article-title":"Beta-blockers are associated with a reduction in COPD exacerbations","volume":"71","author":"Bhatt","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.arbres.2024.01.013_bib0845","doi-asserted-by":"crossref","first-page":"7961","DOI":"10.2147\/IJGM.S295467","article-title":"Optimal management of heart failure and chronic obstructive pulmonary disease: clinical challenges","volume":"15","author":"Cuthbert","year":"2022","journal-title":"Int J Gen Med"},{"key":"10.1016\/j.arbres.2024.01.013_bib0850","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2024.01.013_bib0855","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2024.01.013_bib0860","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3109\/15412555.2015.1099620","article-title":"Antiplatelet treatment reduces all-cause mortality in COPD patients: a systematic review and meta-analysis","volume":"13","author":"Pavasini","year":"2016","journal-title":"COPD"},{"key":"10.1016\/j.arbres.2024.01.013_bib0865","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41533-018-0074-x","article-title":"The association of aspirin use with severity of acute exacerbation of chronic obstructive pulmonary disease: a retrospective cohort study","volume":"28","author":"Goto","year":"2018","journal-title":"NPJ Prim Care Respir Med"},{"key":"10.1016\/j.arbres.2024.01.013_bib0870","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","article-title":"SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe","volume":"42","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.arbres.2024.01.013_bib0875","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1093\/eurheartj\/ehab312","article-title":"SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions","volume":"42","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.arbres.2024.01.013_bib0880","first-page":"CD010177","article-title":"Long-acting beta2-agonists for chronic obstructive pulmonary disease","author":"Kew","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.arbres.2024.01.013_bib0885","first-page":"CD009552","article-title":"Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease","volume":"2015","author":"Cheyne","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.arbres.2024.01.013_bib0890","series-title":"Procesos asistenciales compartidos entre Atenci\u00f3n Primaria y Cardiolog\u00eda. Cap\u00edtulo 2. Disnea. Sociedad Espa\u00f1ola de Cardiolog\u00eda (SEC) y Sociedad Espa\u00f1ola de Medicina Familiar y Comunitaria (semFYC)","author":"Murga","year":"2015"},{"key":"10.1016\/j.arbres.2024.01.013_bib0895","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S2213-2600(19)30190-0","article-title":"Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial","volume":"7","author":"Pascoe","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arbres.2024.01.013_bib0900","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01798-2020","article-title":"Can simvastatin reduce COPD exacerbations? A randomised double-blind controlled study","volume":"58","author":"Schenk","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2024.01.013_bib0905","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1056\/NEJMoa1403086","article-title":"Simvastatin for the prevention of exacerbations in moderate-to-severe COPD","volume":"370","author":"Criner","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2024.01.013_bib0910","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1056\/NEJMoa1908142","article-title":"Metoprolol for the prevention of acute exacerbations of COPD","volume":"381","author":"Dransfield","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Archivos de Bronconeumolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289624000152?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289624000152?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T22:42:58Z","timestamp":1759531378000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300289624000152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":91,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0300289624000152"],"URL":"https:\/\/doi.org\/10.1016\/j.arbres.2024.01.013","relation":{},"ISSN":["0300-2896"],"issn-type":[{"value":"0300-2896","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multidisciplinary Management of Patients With Chronic Obstructive Pulmonary Disease and Cardiovascular Disease","name":"articletitle","label":"Article Title"},{"value":"Archivos de Bronconeumolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arbres.2024.01.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Espa\u00f1a, S.L.U. on behalf of SEPAR.","name":"copyright","label":"Copyright"}]}}